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2nd
generation
DES
1st
generation
DES BMS p-value
Diabetes mellitus 57(53.3%) 68(48.9%) 19(36.5%) 0.14
ACS presentation 56(52.8%) 81(58.3%) 28(53.9%) 0.67
Duration from stent
implantation (yrs)
1.10.8 3.32.1 5.85.6 <0.001
Total stent length (mm) 32.218.7 29.416.1 21.813.5 0.001
Average reference lumen
area (mm2)
6.41.9 6.31.8 6.32.3 0.99
Minimum lumen area
(MLA) (mm2)
2.60.7 2.50.8 2.70.7 0.25
Minimum stent area (MSA) 4.71.6 4.91.6 6.42.2 <0.001
MSA <5mm2 69.2% 56.8% 28.8% <0.001
%NIH at MLA site 52.316.9 56.116.0 60.912.8 0.006
Diffuse ISR 28.0% 30.2% 28.8% 0.01
Stent fracture, n (%) 8.3% 5.8% 0.0% 0.10
Stent malapposition, n (%) 10.3% 10.1% 7.7% 0.86
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: Although the mechanisms of restenosis seem to be similar between 1st
and 2nd generation DES, restenotic DES were characterized by more co-existent
mechanical complications (underexpansion and strut fracture) and less neointimal
hyperplasia than restenotic BMS.
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Background: Additional placement of limus stents (Sirolimus-eluting stent [SES] or
Everolimus-eluting stents [EES]) for the treatment of in-stent restenosis of SES (SES-
ISR) has been a matter of controversy. This prompted us to assess the clinical out-
comes of additional limus-stent in patients presenting with SES-ISR comparing with
balloon angioplasty (BA).
Methods: Enrollment included patients with SES-ISR undergoing repeat target lesion
revascularization (TLR). The patients were grouped according to treatment into EES,
SES and BA groups. The end points were a comparison of major adverse cardiac
events (MACE) composed by all-cause mortality, myocardial infarction and TLR, as
well as incidence of deﬁnite stent thrombosis (ST).
Results: Overall, 310 patients with SES-ISR were treated with [EES (n¼43), SES
(n¼102) and BA (n¼165)]. The baseline characteristics were similar among the
3 groups. The incidence of 1-year MACE was similar among the 3 groups (14.6%,
18%, 20%; respectively; p¼0.72). The incidence of ST was 0% in all the groups.
When the restenotic lesions were classiﬁed into the ﬁrst ISR versus recurrent ISR,
MACE-free rate for recurrent ISR was signiﬁcantly lower when compared with the
ﬁrst ISR for the entire cohort. (67.4% vs 83.8%; p¼0.006) (Figure). This was also
observed in the limus-stent treatment group (66.7% vs 85.5%; p¼0.029).Conclusions: The outcome of patients treated for SES-ISR is similar among ﬁrst- or
second-generation DES and BA. Patients with recurrent ISR are doing poorly even
with second-generation limus-stent.B192 JACC Vol 64/11/Suppl B j SeptembeTCT-660
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Background: Little is known about the effect of sirolimus-eluting stent (SES) im-
plantation in in-stent restenosis (ISR) lesion more than ﬁve years. We aimed to
compare the clinical outcomes up to nine years after the ﬁrst SES implantation be-
tween in ISR lesion and in de novo lesion.
Methods: A total of 395 patients underwent the ﬁrst SES implantation between
November 2002 and December 2004. There were 139 patients for ISR lesion and 256
patients for de novo lesion. We evaluated stent thrombosis (ST) and target lesion
revascularization (TLR) from the SES implantation to ﬁve years and beyond ﬁve
years. ST was deﬁned deﬁnite ST according to the Academic Research Consortium
deﬁnition.
Results: Complete nine-year follow-up was achieved in 91.9% (363/395). The cumu-
lative incidences of nine-year ST were 5.6% in the ISR group and 2.3% in the de novo
group (p¼0.17): TLR, 45.6% and 20.2% (p< 0.001) respectively. As the ﬁgure shows,
the TLR rate in ISR group was signiﬁcantly higher than in de novo group through nine
years, and the difference of the TLR rate in two groups increased in this period.Conclusions: The incidence of TLR after the SES implantation in ISR lesion was
signiﬁcantly higher than that in de novo lesion and the difference of the TLR rate
between in two lesions became more clear through nine years, although the incidence
of ST had no signiﬁcant difference in two lesions.
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Background: Clinical trials have shown a short term beneﬁt of drug eluting stents
(DES) compared to vascular brachytherapy (VBT) for the treatment of in-stent
restenosis (ISR). The long term beneﬁts of DES vs. VBT are conﬂicting in the
literature. This study aimed to do a meta-analysis of long term outcomes of DES
compared to VBT for treatment of ISR.
Methods: PubMed, EMBASE, Cochrane Central and unpublished data were searched
for cohort studies and randomized controlled trials (RCTs) that directly compared
VBT to DES for the treatment of ISR. We evaluated outcomes at 2 to 5 years of follow
up. Random-effects model was used for calculation of odds ratio (OR).
Results:We included 1,364 patients from 5 studies, of which 3 were RCTs. VBT was
used to treat ISR in 677 (49.6%) patients. After a 2 to 5 year follow up, no signiﬁcant
difference was found between treatment groups regarding myocardial infarction
(p¼0.50), stent thrombosis (p¼0.88), cardiovascular mortality (p¼0.35) and overall
mortality (p¼0.72). Target lesion revascularization (TLR; OR 2.39; CI 1.56-3.68;
p< 0.001) and target vessel revascularization (TVR; OR 2.27; CI 1.02-5.21; p¼0.04)
were signiﬁcantly increased in patients who received VBT. As illustrated in ﬁgure 1,
subanalysis including only RCTs showed consistent long-term beneﬁt of DES over
VBT for TLR (p¼0.01) and TVR (p¼0.04).r 13–17, 2014 j TCT Abstracts/Coronary Lesions - In-stent Restenosis
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: This study suggests that DES are associated with decreased long term
revascularization procedures when compared to VBT for the treatment of ISR. This
beneﬁt does not appear to be associated with a signiﬁcant reduction in mortality or
myocardial infarction.
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Background: 2nd generation drug eluting stent (2nd DES) is known to be different
from 1st generation drug eluting stent (1st DES) in various aspects. So the optimal
strategy to treat in-stent restenosis of 2nd DES could be different from that of 1st DES.
Although most of recent coronary intervention use 2nd DES, there seems to be no
prior report focusing solely on this issue.
Methods: Among patients who received de novo PCI with 2nd DES between 2011 to
2013 in our hospital, there are 47 patients who encountered in-stent restenosis and
then revascularized, and also received follow up coronary angiography 9 month after
the revascularization, the strategy of which was at the operator’s discretion. We
analyze the outcome of the 47 patients retrospectively. Among them, 10 (21%) was
stent edge restenosis, 24 (51%) was focal in-stent restenosis, and 13 (28%) was diffuse
in-stent restenosis. Plain Old Balloon Angioplasty (POBA) was applied to 18 (38%)
patients, another DES was implanted to 29 (62%) patients.
Results: To focal in-stent restenosis, besides POBA therapy result in high re-reste-
nosis rate, another DES implantation signiﬁcantly reduced re-restenosis (0.61 vs 0.09,
P< 0.01). On the other hand, to diffuse in-stent restenosis, POBA and another
DES implantation did not differ signiﬁcantly, whose restenosis rates were 0.25 and
0.44, respectively (p¼0.5). Overall, another DES implantation signiﬁcantly reduced
re-restenosis compared to POBA (0.56 vs 0.17, p< 0.01).
Conclusions: Comparing POBA with another DES implantation as the therapy of 2nd
DES restenosis, POBA results in higher re-restenosis rate compared to another DES
implantation to focal type restenosis. But to diffuse type restenosis, POBA and another
DES implantation do not differ signiﬁcantly in their re-restenosis rates.
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Background: Presentation with symptoms such as chest pain and angina following
percutaneous coronary intervention (PCI) is not uncommon. These symptoms can be
indicative of in-stent restenosis (ISR), with traditional diagnostic work-up consisting
of invasive coronary angiography (ICA), non-invasive stress imaging, or coronary
computed tomographic angiography (CCTA). At present, the comparative costs of
evaluation strategies by invasive vs. non-invasive methods remain unknown
Methods: We developed a decision analytic model to determine the 2-year costs
for individuals undergoing PCI, measured by downstream costs per patient undergoing
PCI with suspected ISR. Costs included testing costs and costs due to complications of
testing using Medicare reimbursement rates for the United States. PCI was modeled
for both metallic stents and bioresorbable scaffolds (BRS), with stents dichotomized
as vs.< 3.0mm in diameter. An invasive testing strategy consisting of direct referral to
ICA was compared to 2 non-invasive strategies. Non-invasive diagnostic strategies
included CCTA followed by ICA or stress testing by single photon emission computed
tomography (SPECT) followed by ICA for abnormal or indeterminate results.
Results: The overall 2-year costs per patient were equivalent between individuals
undergoing PCI with metallic stents and BRS for an ICA-based strategy (metallic stent:
$1,547, BRS: $1,547) and slightly lower with BRS for a stress testing-based strategy
(metallic stent: $1,221, BRS: $1,206). However, for a CCTA-based strategy, BRS was
associated with lower costs than metallic stents in both < 3.0mm vessels (metallic
stent: $1,133, BRS: $772) and  3.0mm vessels (metallic stent: $1,342, BRS: $431).
Test-related complication rates for testing strategies ranged from 0.8% to 2.0%.
Conclusions: In individuals with suspected ISR after PCI, use of BRS with a down-
stream non-invasive evaluation strategy results in signiﬁcantly lower costs than for
metallic stents evaluated by either invasive or non-invasive methods. In particular, sig-
niﬁcant cost reductions occur when BRS is utilized for PCI and ISR evaluated by CCTA.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaValvular disease - Aortic: TAVR Imaging
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Background: The transthoracic echocardiographic (TTE) evaluation of the severity of
residual aortic regurgitation (AR) following transcatheter aortic valve implantation
(TAVI) has been controversial and lacks validation. This study sought to compare
TTE and cardiac magnetic resonance (CMR) for assessment of AR in patients un-
dergoing transcatheter aortic valve implantation (TAVI) with a balloon-expandable
valve.
Methods: TTE and CMR exams were performed pre-TAVI in 50 patients and were
repeated post-procedure in 42 patients. All imaging data were analyzed in centralized
core laboratories.
Results: The severity of native AR as determined by multi-parametric TTE
approach correlated well with the regurgitant volume and regurgitant fraction
determined by CMR prior to TAVI (Rs¼0.79 and 0.80, respectively; p< 0.001
for both). However, after TAVI, the correlation between the prosthetic AR
severity assessed by TTE and regurgitant volume and fraction measured by CMR
was only modest (Rs¼0.59 and 0.59, respectively; p< 0.001 for both), with an
underestimation of AR severity by TTE in 61.9% of patients (1 grade in 59.5%).
The TTE jet diameter in parasternal view and the multi-parametric approach
(Rs¼0.62 and Rs¼0.59, respectively; both with p< 0.001) showed the best
correlation with CMR regurgitant fraction post-TAVI. The circumferential extent
of prosthetic paravalvular regurgitation showed a poor correlation with CMR
regurgitant volume and fraction (Rs ¼0.32; p¼0.084; Rs ¼0.36, p¼0.054,
respectively).
Conclusions: The severity of AR following TAVI with a balloon-expandable valve
was underestimated by echocardiography as compared to CMR. The jet diameter, but
not the circumferential extent of the leaks, and the multi-parametric echocardiography
integrative approach best correlated with CMR ﬁndings. These results provide
important insight into the evaluation of AR severity post-TAVI.TCT-665
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Background: Early stent valve thrombosis after transcatheter aortic valve replacement
(TAVR) is a rare complication diagnosed based on the appearance of clinical
symptoms of heart failure and echocardiographic ﬁndings. Following TAVR, trans-
thoracic echocardiography (TTE) is performed to assess transcatheter heart valvelvular disease - Aortic: TAVR Imaging B193
